Market Research Logo

Cardiac Assist Devices (CAD) Global Market – Forecast To 2024

Cardiac Assist Devices (CAD) Global Market – Forecast To 2024

The heart conditions are considered advanced or end stage heart failure, when conventional heart therapies and management strategies no longer work. The reduced ability of the heart to pump blood and maintain normal bodily function leads to heart failure. Heart transplantation is currently the preferred treatment for end-stage heart failure. The availability of donor hearts is insufficient to meet the required demand and many patients are not eligible for transplantation due to age and other health conditions. The Cardiac assist devices (CAD) i.e. VAD, TAH and IABP are used to treat various conditions related to heart such as end stage heart failure, refractory angina pectoris, post-cardiopulmonary bypass shock, myocardial infarction, myocarditis, etc. The ventricular assist device is a mechanical pump that supports heart function and blood flow by taking on the workload of the left ventricle, right ventricle or both left and right ventricles helping the heart to pump oxygenated blood to the rest of the body. The indication for VAD use is acute cardiogenic shock (post cardiac surgery, myocarditis and massive myocardial infarction) and chronic heart failure. An artificial heart (TAH) is a mechanical assist device for persons with biventricular heart failure and heart transplant candidate which replaces both native ventricles and all four chambers of heart, thereby eliminating the symptoms of cardiac insufficiency or heart failure. Intra-aortic balloon pump (IABP) is placed in aorta to help the heart to pump more blood by reducing the workload on the heart and improves the function of the left ventricle as this is the chamber that pumps blood into the aorta. IABP is used in conditions such as acute mitral valve regurgitation or severe heart failure, left ventricular failure, unstable angina, etc.

According to IQ4I Analysis, CAD market is expected to grow at double digit CAGR to reach $4,255.5 million by 2024. Products of Cardiac assist devices market is segmented into Ventricular Assist Device {(Left Ventricular Assist Devices (LVAD), Right Ventricular Assist Devices (RVAD) and Biventricular Assist Devices (Bi-VAD)}, Total Artificial Heart (TAH) and Intra-Aortic Balloon Pump (IABP). CAD market by pump type is segmented into Pulsating or Pneumatic Pump and Continuous Flow Pump. The continuous flow pump is further segmented into Axial flow pump and Centrifugal flow pump. CAD market by implant type is segmented into Extracorporeal CAD, Intracorporeal CAD and Percutaneous CAD. CAD market by patient type is segmented into Adult and Pediatric CAD. Applications of Cardiac assist devices are segmented into Bridge to Transplant (BTT), Bridge to destination (BTD), Bridge to Recovery (BTR). End-User of Cardiac assist devices are segmented into hospitals, academics & research institutes and other End-user (catheterization labs and ambulatory settings).

This report concentrates on Cardiac assist devices that are placed internally (VAD, TAH), externally (VAD) and percutaneously (VAD and IABP) for treating end-stage heart failure, cardiogenic shock, ventricular insufficiency, acute heart attack, intraoperative and postoperative cardiac procedures. The mechanical circulatory devices like extracorporeal membrane oxygenation (ECMO) or Heart lung machine and other cardiac assist devices like pacemakers and defibrillators are not considered in Cardiac assist devices global market report.

Some of the key players of the Cardiac assist devices are Abbott Laboratories (U.S.), Medtronic PLC (Ireland), Abiomed (U.S.), Reliant Heart (U.S.), Fresenius Medical Care AG & Co. KGaA Care AG & Co. KGaA (Germany), Getinge Group (Sweden), Syncardia Systems, Inc (U.S.), Zeon Corporation (Japan), Teleflex Incorporated (U.S.), etc.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Others
  • Europe
  • Germany
  • France
  • U.K.
  • Others
  • Asia-Pacific
  • Japan
  • China
  • India
  • Others
  • Rest of the World (RoW)
  • Brazil
  • Rest of Latin America
  • Middle East and others


1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing incidence of heart failure
3.3.1.2 Shortage of heart donors
3.3.1.3 Technological advancements in VAD
3.3.1.4 Rising geriatric population
3.3.1.5 Vast pipeline products
3.3.1.6 Increase in funding for CAD research
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Adverse events and complication with the implantations of CAD
3.3.2.2 Cost of the devices
3.3.2.3 Lack of skilled and trained professionals
3.3.2.4 Stringent regulatory guidelines
3.3.2.5 Availability of alternative products
3.3.2.6 Cardiac assist devices product recalls due to FDA mandates
3.4 REGULATORY AFFAIRS
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
3.4.2 U.S.
3.4.3 CANADA
3.4.4 EUROPE
3.4.5 CHINA
3.4.6 JAPAN
3.4.7 INDIA
3.5 REIMBURSEMENT SCENARIO
3.5.1 REIMBURSEMENT TABLE
3.5.1.1 Ventricular assist device reimbursement
3.5.1.2 CAD physician reimbursement
3.6 UPCOMING TECHNOLOGY
3.7 CLINICL TRIAL DATA
3.8 PATENT TRENDS
3.9 TECHNOLOGICAL ADVANCEMENTS
3.9.1 INTRODUCTION
3.9.2 PERCUTANEOUS VENTRICULAR ASSIST DEVICES (PVAD)
3.9.3 MEDICAL COATINGS FOR CARDIAC ASSIST DEVICES
3.9.4 ADVANCEMENT IN BLOOD FLOW TECHNOLOGY
3.10 PORTER’S FIVE FORCE ANALYSIS
3.10.1 THREAT OF NEW ENTRANTS
3.10.2 THREAT OF SUBSTITUTES
3.10.3 BARGAINING POWER OF SUPPLIERS
3.10.4 BARGAINING POWER OF BUYERS
3.10.5 COMPETITIVE RIVALRY
3.11 SUPPLY CHAIN ANALYSIS
3.12 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.12.1 CARDIAC ASSIST DEVICE GLOBAL MARKET SHARE ANALYSIS
3.12.2 VENTRICULAR ASSIST DEVICE GLOBAL MARKET SHARE ANALYSIS
3.12.3 INTRA-AORTIC BALLOON PUMP GLOBAL MARKET SHARE ANALYSIS
3.13 CARDIAC ASSIST DEVICES NUMBER OF UNITS BY REGION
3.13.1 VENTRICULAR ASSIST DEVICES NUMBER OF UNITS BY REGION
3.13.1.1 Extracorporeal ventricular assist devices
3.13.1.2 Intracorporeal ventricular assist devices
3.13.1.3 Percutaneous ventricular assist devices
3.13.2 TOTAL ARTIFICIAL HEART NUMBER OF UNITS BY REGION
3.14 COMPARISON OF CARDIAC ASSIST DEVICES
4 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY PRODUCT
4.1 INTRODUCTION
4.2 VENTRICULAR ASSIST DEVICES (VAD)
4.2.1 LEFT VENTRICULAR ASSIST DEVICES (LVAD)
4.2.2 RIGHT VENTRICULAR ASSIST DEVICES (RVAD)
4.2.3 BI-VENTRICULAR ASSIST DEVICES (BIVAD)
4.3 INTRA-AORTIC BALLOON PUMPS (IABP)
4.4 TOTAL ARTFICIAL HEART (TAH)
5 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY IMPLANT TYPE
5.1 INTRODUCTION
5.2 EXTRACORPOREAL OR PARACORPOREAL CAD
5.3 INTRACORPOREAL CAD
5.4 PERCUTANEOUS CAD
6 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY PUMP TYPE
6.1 INTRODUCTION
6.2 PULSATILE FLOW PUMP
6.3 CONTINUOUS FLOW PUMP
6.3.1 CENTRIFUGAL FLOW PUMP
6.3.2 AXIAL FLOW PUMP
7 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY PATIENT TYPE
7.1 INTRODUCTION
7.2 PEDIATRIC CAD
7.3 ADULT CAD
8 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 BRIDGE TO TRANSPLANT (BTT)
8.3 BRIDGE TO DESTINATION THERAPY (BTD)
8.4 BRIDGE TO RECOVERY (BTR)
9 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY END-USERS
9.1 INTRODUCTION
9.2 HOSPITALS
9.3 ACADEMICS & RESEARCH INSTITUTES
9.4 OTHER END-USERS
10 REGIONAL ANALYSIS
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 U.S.
10.2.2 OTHERS
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 U.K.
10.3.4 OTHERS
10.4 APAC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 OTHERS
10.5 ROW
10.5.1 BRAZIL
10.5.2 REST OF LATIN AMERICA
10.5.3 MIDDLE EAST AND OTHERS
11 COMPANY DEVELOPMENTS
11.1 INTRODUCTION
11.2 APPROVALS
11.3 ACQUISITIONS
11.4 PARTNERSHIPS
11.5 OTHER DEVELOPMENTS
12 MAJOR COMPANIES
12.1 ABBOTT LABORATORIES
12.1.1 OVERVIEW
12.1.2 FINANCIALS
12.1.3 PRODUCT PORTFOLIO
12.1.4 KEY DEVELOPMENTS
12.1.5 BUSINESS STRATEGY
12.1.6 SWOT ANALYSIS
12.2 ABIOMED, INC.
12.2.1 OVERVIEW
12.2.2 FINANCIALS
12.2.3 PRODUCT PORTFOLIO
12.2.4 KEY DEVELOPMENTS
12.2.5 BUSINESS STRATEGY
12.2.6 SWOT ANALYSIS
12.3 BERLIN HEART GMBH
12.3.1 OVERVIEW
12.3.2 FINANCIALS
12.3.3 PRODUCT PORTFOLIO
12.3.4 KEY DEVELOPMENTS
12.3.5 BUSINESS STRATEGY
12.3.6 SWOT ANALYSIS
12.4 BIVACOR INC.
12.4.1 OVERVIEW
12.4.2 FINANCIALS
12.4.3 PRODUCT PORTFOLIO
12.4.4 KEY DEVELOPMNTS
12.4.5 BUSINESS STRATEGY
12.4.6 SWOT ANALYSIS
12.5 CARMAT SA
12.5.1 OVERVIEW
12.5.2 FINANCIALS
12.5.3 PRODUCT PORTFOLIO
12.5.4 KEY DEVELOPMNTS
12.5.5 BUSINESS STRATEGY
12.5.6 SWOT ANALYSIS
12.6 FRESENIUS MEDICAL CARE AG & CO. KGAA (XENIOS AG)
12.6.1 OVERVIEW
12.6.2 FINANCIALS
12.6.3 PRODUCT PORTFOLIO
12.6.4 KEY DEVELOPMNTS
12.6.5 BUSINESS STRATEGY
12.6.6 SWOT ANALYSIS
12.7 GETINGE GROUP (MAQUET)
12.7.1 OVERVIEW
12.7.2 FINANCIALS
12.7.3 PRODUCT PORTFOLIO
12.7.4 KEY DEVELOPMENTS
12.7.5 BUSINESS STRATEGY
12.7.6 SWOT ANALYSIS
12.8 MEDTRONIC, PLC
12.8.1 OVERVIEW
12.8.2 FINANCIALS
12.8.3 PRODUCT PORTFOLIO
12.8.4 KEY DEVELOPMENTS
12.8.5 BUSINESS STRATEGY
12.8.6 SWOT ANALYSIS
12.9 RELIANTHEART INC.
12.9.1 OVERVIEW
12.9.2 FINANCIALS
12.9.3 PRODUCT PORTFOLIO
12.9.4 KEY DEVELOPMNTS
12.9.5 BUSINESS STRATEGY
12.9.6 SWOT ANALYSIS
12.10 SYNCARDIA SYSTEMS, INC
12.10.1 OVERVIEW
12.10.2 FINANCIALS
12.10.3 PRODUCT PORTFOLIO
12.10.4 KEY DEVELOPMENTS
12.10.5 BUSINESS STRATEGY
12.10.6 SWOT ANALYSIS
12.11 TELEFLEX INCORPORATED
12.11.1 OVERVIEW
12.11.2 FINANCIALS
12.11.3 PRODUCT PORTFOLIO
12.11.4 KEY DEVELOPMENTS
12.11.5 BUSINESS STRATEGY
12.11.6 SWOT ANALYSIS
12.12 ZEON CORPORATION
12.12.1 OVERVIEW
12.12.2 FINANCIALS
12.12.3 PRODUCT PORTFOLIO
12.12.4 KEY DEVELOPMENTS
12.12.5 BUSINESS STRATEGY
12.12.6 SWOT ANALYSIS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report